Details of the Drug Combination

General Information of Drug Combination (ID: DCGA62Z)

Drug Combination Name

Cyproterone acetate Triptorelin

Indication

Disease Entry	Status	REF
Gender Dysphoria	Phase 4	[1]

Component Drugs

Cyproterone acetate DMLMOIJ

Triptorelin DMTK4LS

N.A.

Small molecular drug

2D MOL

3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)

Cyproterone acetate Interacts with 1 DME Molecule(s)

DME Name	DME ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	DE4LYSA	CP3A4_HUMAN	Metabolism	[5]
------------------------------------------------------------------------------------

Cyproterone acetate Interacts with 9 DOT Molecule(s)

DOT Name	DOT ID	UniProt ID	Mode of Action	REF
Cytochrome P450 3A4 (CYP3A4)	OTQGYY83	CP3A4_HUMAN	Increases Expression	[6]
Follitropin subunit beta (FSHB)	OTGLS283	FSHB_HUMAN	Decreases Expression	[7]
Lutropin subunit beta (LHB)	OT5GBOVJ	LSHB_HUMAN	Decreases Expression	[7]
Apolipoprotein A-I (APOA1)	OT5THARI	APOA1_HUMAN	Affects Expression	[8]
Apolipoprotein A-II (APOA2)	OTQ3HGTC	APOA2_HUMAN	Affects Expression	[8]
Cytochrome P450 1A1 (CYP1A1)	OTE4EFH8	CP1A1_HUMAN	Decreases Activity	[9]
Prostate-specific antigen (KLK3)	OTFGSBFJ	KLK3_HUMAN	Decreases Expression	[10]
Androgen receptor (AR)	OTUBKAZZ	ANDR_HUMAN	Decreases Expression	[11]
Kallikrein-2 (KLK2)	OT9RE37R	KLK2_HUMAN	Decreases Expression	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 DOT(s)

Indication(s) of Triptorelin

Disease Entry	ICD 11	Status	REF
Infertility	GB04	Approved	[2]
Solid tumour/cancer	2A00-2F9Z	Approved	[3]
Prostate cancer	2C82.0	Phase 4	[4]

Triptorelin Interacts with 1 DTT Molecule(s)

DTT Name	DTT ID	UniProt ID	Mode of Action	REF
Gonadotropin-releasing hormone receptor (GNRHR)	TT8R70G	GNRHR_HUMAN	Modulator	[12]
------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT02715232) Effects of Sex Steroids on the Serotonin System
2	Triptorelin FDA Label
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1177).
4	ClinicalTrials.gov (NCT00633347) Use of Antagonist Versus Agonist GnRH in Oocyte Recipient Endometrium Preparation. U.S. National Institutes of Health.
5	Progestogens in menopausal hormone therapy. Prz Menopauzalny. 2015 Jun;14(2):134-43.
6	Receptor-dependent regulation of the CYP3A4 gene. Toxicology. 2002 Dec 27;181-182:199-202.
7	Twenty-one day administration of dienogest reversibly suppresses gonadotropins and testosterone in normal men. J Clin Endocrinol Metab. 2002 May;87(5):2107-13. doi: 10.1210/jcem.87.5.8514.
8	Antiandrogenic therapy can cause coronary arterial disease. Int J Urol. 2005 Oct;12(10):886-91. doi: 10.1111/j.1442-2042.2005.01145.x.
9	Structure-based virtual screening of CYP1A1 inhibitors: towards rapid tier-one assessment of potential developmental toxicants. Arch Toxicol. 2021 Sep;95(9):3031-3048. doi: 10.1007/s00204-021-03111-2. Epub 2021 Jun 28.
10	Dramatic suppression of plasma and urinary prostate specific antigen and human glandular kallikrein by antiandrogens in male-to-female transsexuals. J Urol. 2000 Mar;163(3):802-5.
11	Antiandrogenic activity of norgestimate in a human androgen-dependent stable-transfected cell line. Gynecol Endocrinol. 2007 Apr;23(4):193-7. doi: 10.1080/09513590701214414.
12	Regulation of GnRH I receptor gene expression by the GnRH agonist triptorelin, estradiol, and progesterone in the gonadotroph-derived cell line alphaT3-1. Endocrine. 2006 Aug;30(1):139-44.